LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, "LAVA," or "Company"), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference.
荷蘭烏得勒支和費城，2024年5月6日（GLOBE NEWSWIRE）——專注於開發其專有的雙特異伽瑪-三角洲（2）T細胞參與劑Gammabody平台的臨床階段免疫腫瘤學公司LAVA Therapeutics N.V.（納斯達克股票代碼：LVAX，“LAVA” 或 “公司”）今天宣佈，LAVA Therapeutics總裁兼首席執行官斯蒂芬·赫利將參與在 Citizens JMP 生命科學大會的爐邊談話中。
Presentation Details
Format: Fireside Chat
Date: Monday, May 13, 2024
Time: 10:00 a.m. ET
演示詳情
格式：爐邊聊天
日期：2024 年 5 月 13 日星期一
時間：美國東部時間上午 10:00
A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at The replay will be archived for 90 days following the presentation date.
可以在LAVA Therapeutics網站投資者關係部分的 “活動” 選項卡下觀看爐邊談話的網絡直播。重播將在演示日期後的90天內存檔。
譯文內容由第三人軟體翻譯。